Higher CD56 Expression on Multiple Myeloma Cells Increases CD38 Expression, Reduces Intracellular NAD+ Levels, and Enhances the Efficacy of Daratumumab-Based Treatment Strategies
Giulia Giorgetti(Dana-Farber Cancer Institute), Michele Cea(Azienda Ospedaliera S.Maria), Daniela Fenoglio(Ospedale Policlinico San Martino), Roberto M. Lemoli(University of Genoa), Santina Bruzzone(University of Genoa), Aimable Nahimana(University of Lausanne), Pamela Becherini(Ospedale Policlinico San Martino), Nikhil C. Munshi(Dana-Farber Cancer Institute), Mariateresa Fulciniti(Dana-Farber Cancer Institute), Chiara Uras(University of Genoa), Claudia Martinuzzi(Ospedale Policlinico San Martino), Debora Soncini(University of Genoa), Elena Maroto-Martín(Harvard University), Anaïs Schavgoulidze(Inserm), Jessica Ng Fong(Dana-Farber Cancer Institute), Andrea Benzi(University of Genoa)
Cited by 2
Related Papers
Signatures of mutational processes in human cancer
|Nature|2013|10.1k
Anti-BCMA CAR T-Cell Therapy bb2121 in Relapsed or Refractory Multiple Myeloma
|New England Journal of Medicine|2019|1.7k
Somatic<i>SF3B1</i>Mutation in Myelodysplasia with Ring Sideroblasts
|New England Journal of Medicine|2011|1.2k
Heterogeneity of genomic evolution and mutational profiles in multiple myeloma
|Nature Communications|2014|906